Tardive Dyskinesia News and Research

RSS
Tardive dyskinesia is a neurological syndrome caused by the long-term use of neuroleptic drugs. Neuroleptic drugs are generally prescribed for psychiatric disorders, as well as for some gastrointestinal and neurological disorders. Tardive dyskinesia is characterized by repetitive, involuntary, purposeless movements. Features of the disorder may include grimacing, tongue protrusion, lip smacking, puckering and pursing, and rapid eye blinking. Rapid movements of the arms, legs, and trunk may also occur. Involuntary movements of the fingers may appear as though the patient is playing an invisible guitar or piano.
Study reveals safety, efficacy of brexpiprazole for schizophrenia patients with severe psychotic symptoms

Study reveals safety, efficacy of brexpiprazole for schizophrenia patients with severe psychotic symptoms

Sunovion announces results from Phase 3 clinical study of new drug in children, adolescents with bipolar depression

Sunovion announces results from Phase 3 clinical study of new drug in children, adolescents with bipolar depression

New approaches to prevent or treat antipsychotic-induced supersensitivity psychosis

New approaches to prevent or treat antipsychotic-induced supersensitivity psychosis

FDA grants approval for first drug to treat adults with tardive dyskinesia

FDA grants approval for first drug to treat adults with tardive dyskinesia

New drug can reduce tardive dyskinesia in patients with schizophrenia, mood disorder

New drug can reduce tardive dyskinesia in patients with schizophrenia, mood disorder

Deutetrabenazine may help improve chorea symptoms in patients with HD

Deutetrabenazine may help improve chorea symptoms in patients with HD

Neurocrine Biosciences reports net loss of $29.3 million for fourth quarter 2015

Neurocrine Biosciences reports net loss of $29.3 million for fourth quarter 2015

Neurocrine Biosciences announces positive data from NBI-98854 Phase III trial in tardive dyskinesia

Neurocrine Biosciences announces positive data from NBI-98854 Phase III trial in tardive dyskinesia

Neurocrine completes enrollment in Phase III clinical trial of NBI-98854 in tardive dyskinesia patients

Neurocrine completes enrollment in Phase III clinical trial of NBI-98854 in tardive dyskinesia patients

Allergan announces U.S. availability of SAPHRIS 2.5 mg tablets for children with bipolar I disorder

Allergan announces U.S. availability of SAPHRIS 2.5 mg tablets for children with bipolar I disorder

Neurocrine reports net loss of $1.2 million for first quarter 2015

Neurocrine reports net loss of $1.2 million for first quarter 2015

Neurocrine Biosciences, Mitsubishi Tanabe to develop and commercialize NBI-98854 in select Asian markets

Neurocrine Biosciences, Mitsubishi Tanabe to develop and commercialize NBI-98854 in select Asian markets

NeuroPerspective features comprehensive reviews of schizophrenia, spinal cord injury

NeuroPerspective features comprehensive reviews of schizophrenia, spinal cord injury

Altos Therapeutics announces issuance of Mexican patent covering dopamine D2/D3 drug candidates

Altos Therapeutics announces issuance of Mexican patent covering dopamine D2/D3 drug candidates

Janssen announces submission of NDA for three-month paliperidone palmitate

Janssen announces submission of NDA for three-month paliperidone palmitate

Neurocrine Biosciences' NBI-98854 drug gets breakthrough designation for tardive dyskinesia

Neurocrine Biosciences' NBI-98854 drug gets breakthrough designation for tardive dyskinesia

Little efficacy difference between old and new antipsychotics

Little efficacy difference between old and new antipsychotics

Mylan releases generic version of Zyprexa Zydis Tablets

Mylan releases generic version of Zyprexa Zydis Tablets

Jazz Pharmaceuticals' Versacloz now commercially available in the U.S. for schizophrenia

Jazz Pharmaceuticals' Versacloz now commercially available in the U.S. for schizophrenia

More antipsychotic medications prescribed to children and adolescents in Germany

More antipsychotic medications prescribed to children and adolescents in Germany

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.